Immuneering Corporation cash flow to debt ratio of -1.19K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Immuneering Corporation's free cash flow has increased -17.42% from $-55.08M last year to $-45.49M, signaling increasing performance

Immuneering Corporation's debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Immuneering Corporation's debt has decreased relative to shareholder equity from 0.10 last year to 0.02 today, signaling strengthened financials

Immuneering Corporation has negative EBITDA, making leverage ratio unreliable

Immuneering Corporation earns at least as much interest as it pays. Interest obligations are fully covered.

Immuneering Corporation has insufficient data to evaluate this check.

Immuneering Corporation's short-term assets of $176.25M exceed its short-term liabilities of $10.07M

Immuneering Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Immuneering Corporation's return on equity of -0.11%, is lower than 15.00%, indicating bad performance

Immuneering Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Immuneering Corporation had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Immuneering Corporation has negative free cash flow, indicating the company is burning cash rather than generating it

Immuneering Corporation has negative free cash flow, indicating cash burn

Immuneering Corporation's yearly earnings has increased -8.21% since last year from $-61.04M to $-56.02M, signaling increasing performance

Immuneering Corporation's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -0.03% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Immuneering Corporation's 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Immuneering Corporation had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Immuneering Corporation had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Immuneering Corporation has insufficient data to evaluate this check.

Immuneering Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Immuneering Corporation is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Immuneering Corporation has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Immuneering Corporation has insufficient data to evaluate this check.

Immuneering Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Immuneering Corporation has a price-to-book ratio of 0.00x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Immuneering Corporation has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue